BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1294 related articles for article (PubMed ID: 9591591)

  • 21. Differentiated thyroid carcinoma in children and adolescents: a 37-year experience in 85 patients.
    Dottorini ME; Vignati A; Mazzucchelli L; Lomuscio G; Colombo L
    J Nucl Med; 1997 May; 38(5):669-75. PubMed ID: 9170425
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Follow-up of differentiated thyroid cancer.
    Pacini F
    Eur J Nucl Med Mol Imaging; 2002 Aug; 29 Suppl 2():S492-6. PubMed ID: 12192551
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Patients treated for differentiated thyroid cancer with negative 131I whole-body scans and elevated thyroglobulin levels: a possible course].
    Gutiérrez Cardo AL; Rodríguez Rodríguez JR; Borrego Dorado I; Navarro González E; Tirado Hospital JL; Vázquez Albertino R
    Rev Esp Med Nucl; 2007; 26(3):138-45. PubMed ID: 17524307
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Radioiodine whole-body scans, thyroglobulin levels, 99mTc-MIBI scans and computed tomography: results in patients with lung metastases from differentiated thyroid cancer.
    Küçük ON; Gültekin SS; Aras G; Ibiş E
    Nucl Med Commun; 2006 Mar; 27(3):261-6. PubMed ID: 16479246
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Comparison of 99Tcm-tetrofosmin with 201Tl and 131I in the detection of differentiated thyroid cancer metastases.
    Nishiyama Y; Yamamoto Y; Ono Y; Takahashi K; Nakano S; Satoh K; Ohkawa M; Tanabe M
    Nucl Med Commun; 2000 Oct; 21(10):917-23. PubMed ID: 11130332
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Recombinant human TSH changes the multidisciplinary approach to patients with differentiated thyroid carcinoma. Two-year experience.
    Giusti M; Zoccola R; Guazzini B; Molinari E; Valenti S; Villa G; Bertolazzi L; Minuto F
    Minerva Endocrinol; 2003 Sep; 28(3):191-203. PubMed ID: 14605601
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Is stimulation of thyroglobulin (Tg) useful in low-risk patients with thyroid carcinoma and undetectable Tg on thyroxin and negative neck ultrasound?
    Rosário PW; Borges MA; Fagundes TA; Franco AC; Purisch S
    Clin Endocrinol (Oxf); 2005 Feb; 62(2):121-5. PubMed ID: 15670185
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Clinical utility of technetium-99m methoxisobutylisonitrile imaging in differentiated thyroid carcinoma: comparison with thallium-201 and iodine-131 Na scintigraphy, and serum thyroglobulin quantitation.
    Dadparvar S; Chevres A; Tulchinsky M; Krishna-Badrinath L; Khan AS; Slizofski WJ
    Eur J Nucl Med; 1995 Nov; 22(11):1330-8. PubMed ID: 8575487
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Are there disadvantages in administering 131I ablation therapy in patients with differentiated thyroid carcinoma without a preablative diagnostic 131I whole-body scan?
    Salvatori M; Perotti G; Rufini V; Maussier ML; Dottorini M
    Clin Endocrinol (Oxf); 2004 Dec; 61(6):704-10. PubMed ID: 15579184
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Thyroid carcinoma: iodine-131-negative whole-body scan reverses to positive after a combination of thyrogen stimulation and withdrawal.
    Kasner DL; Spieth ME; Starkman ME; Zdor-North D
    Clin Nucl Med; 2002 Nov; 27(11):772-80. PubMed ID: 12394123
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The predictive value of serum thyroglobulin in the follow-up of differentiated thyroid cancer.
    Roelants V; Nayer PD; Bouckaert A; Beckers C
    Eur J Nucl Med; 1997 Jul; 24(7):722-7. PubMed ID: 9211756
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Comparison of 99mTc-methoxyisobutyl isonitrile and 201Tl scintigraphy for detection of residual thyroid cancer after 131I ablative therapy.
    Seabold JE; Gurll N; Schurrer ME; Aktay R; Kirchner PT
    J Nucl Med; 1999 Sep; 40(9):1434-40. PubMed ID: 10492361
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Comparison of seven serum thyroglobulin assays in the follow-up of papillary and follicular thyroid cancer patients.
    Schlumberger M; Hitzel A; Toubert ME; Corone C; Troalen F; Schlageter MH; Claustrat F; Koscielny S; Taieb D; Toubeau M; Bonichon F; Borson-Chazot F; Leenhardt L; Schvartz C; Dejax C; Brenot-Rossi I; Torlontano M; Tenenbaum F; Bardet S; Bussière F; Girard JJ; Morel O; Schneegans O; Schlienger JL; Prost A; So D; Archambeaud F; Ricard M; Benhamou E
    J Clin Endocrinol Metab; 2007 Jul; 92(7):2487-95. PubMed ID: 17426102
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Value of FDG PET in papillary thyroid carcinoma with negative 131I whole-body scan.
    Chung JK; So Y; Lee JS; Choi CW; Lim SM; Lee DS; Hong SW; Youn YK; Lee MC; Cho BY
    J Nucl Med; 1999 Jun; 40(6):986-92. PubMed ID: 10452315
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Technetium-99m tetrofosmin single photon emission computed tomography to detect metastatic papillary thyroid carcinoma in patients with elevated human serum thyroglobulin levels but negative I-131 whole body scan.
    Wu HS; Liu FY; Huang WS; Liu YC; Chang CT; Kao CH
    Clin Radiol; 2003 Oct; 58(10):787-90. PubMed ID: 14521888
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Fluorine-18-FDG and iodine-131-iodide uptake in thyroid cancer.
    Feine U; Lietzenmayer R; Hanke JP; Held J; Wöhrle H; Müller-Schauenburg W
    J Nucl Med; 1996 Sep; 37(9):1468-72. PubMed ID: 8790195
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Whole-body Tc-99m sestamibi scintigraphy in the follow-up of differentiated thyroid carcinoma.
    Almeida-Filho P; Ravizzini GC; Almeida C; Borges-Neto S
    Clin Nucl Med; 2000 Jun; 25(6):443-6. PubMed ID: 10836693
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Thyroglobulin, 131I-whole body scintigraphy and risk factors in the follow-up of differentiated thyroid cancer].
    Berding G; Hüfner M; Georgi P
    Nuklearmedizin; 1992 Feb; 31(1):32-7. PubMed ID: 1561118
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Comparison of thyroglobulin and radioiodine scintigraphy during follow-up of patients with differentiated thyroid carcinoma.
    Johansen K; Woodhouse NJ
    Eur J Med; 1992 Nov; 1(7):403-6. PubMed ID: 1341479
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Comparison of whole-body 18F-FDG PET, 99mTc-MIBI SPET, and post-therapeutic 131I-Na scintigraphy in the detection of metastatic thyroid cancer.
    Iwata M; Kasagi K; Misaki T; Matsumoto K; Iida Y; Ishimori T; Nakamoto Y; Higashi T; Saga T; Konishi J
    Eur J Nucl Med Mol Imaging; 2004 Apr; 31(4):491-8. PubMed ID: 14666387
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 65.